
SkinIO Featured in Breakthroughs™ PSA Highlighting AI-Enhanced Skin Imaging and Rapid Connection to Dermatology Care

Multiple Public-service segments spotlight SkinIO's breakthrough approach & mission to
make early skin cancer detection simple and accessible for all.

CHICAGO , IL, UNITED STATES, September 3, 2026 /EINPresswire.com/ -- SkinIO, a skin cancer detection and connection-to-care innovator, is being featured in a national Breakthroughs™ Public Service Announcement focused on improving access to earlier skin cancer detection and helping more people take action on their skin health.



The SkinIO smartphone app allows users to take photos of their skin in 10 minutes. These images are reviewed by a dermatologist who determines whether any concerning spots merit further examination.

Skin cancer detection is one of the most important areas in preventive healthcare because timing matters. When people delay screening, cannot easily access dermatology care, or are unsure whether a skin change needs attention, small concerns can become more serious. The Breakthroughs™ PSA is designed to help educate the public about the importance of earlier detection, timely follow-up, and more accessible pathways to dermatology care.

SkinIO is making it easier for people to take action on their skin health. Using advanced imaging and artificial intelligence, SkinIO captures and analyzes skin images to help identify lesions or

abnormalities that may warrant further evaluation. When a potential concern is identified, this innovative approach helps streamline the path to appropriate follow-up care—supporting earlier detection, faster action, and better access to care.



“SkinIO is honored to be featured as one of the breakthrough innovators in this PSA series,” said Steve Bonner, CEO of SkinIO. “The series provides a careful and complete description of our combination of AI-enhanced technology and rapid connection to care, explaining how earlier detection and swift therapy can help reduce the burden of advanced-stage skin cancer.” Bonner added, “We welcome continued feedback and conversation and look forward to sharing more about our work to improve access, quality, cost, and outcomes in skin cancer detection and care.”

The PSA frames SkinIO’s work within a larger public-health issue: awareness alone is not enough if people cannot easily take the next step. For many individuals, access to a full skin evaluation can be delayed by appointment availability, geography, cost concerns, lack of awareness, or uncertainty about where to begin. SkinIO’s model helps make that first step more approachable by combining technology-enabled skin imaging with a rapid connection to expert dermatology care.

The PSA also emphasizes that AI-enhanced technology is not a replacement for clinical judgment. Instead, it can be used as part of a responsible, connected process that helps identify possible concerns and guide people toward appropriate professional evaluation. This distinction is central to the public-service message: technology can help make detection more accessible, but medical decision-making and follow-up care remain essential.

SkinIO’s mission is direct and ambitious: eradicate advanced-stage skin cancer by making early detection simple, accessible, and equitable for all. Their trusted AI-powered skin imaging and rapid connection to expert dermatology care bring breakthrough prevention to everyone, no matter where they are.

By featuring SkinIO, the Breakthroughs™ PSA series aims to help viewers understand that earlier skin cancer detection is not only a medical issue, but also an access issue. The goal is to encourage people to take skin health seriously, recognize that suspicious or changing lesions deserve attention, and understand that more connected approaches to screening and follow-up can help reduce delays.

The PSA will reach both general and professional audiences nationally, including patients, families, employers, health plans, healthcare organizations, dermatology professionals, and public-health stakeholders interested in prevention, access, and earlier action.

About SkinIO

SkinIO is a skin cancer detection and connection-to-care innovator making it easier for people to
take action on their skin health. Using advanced imaging, artificial intelligence, and rapid connection to expert dermatology care, SkinIO helps identify skin lesions or abnormalities that may warrant further evaluation and supports a faster path to appropriate follow-up care.
For more info:
https://www.skinio.com/

About Breakthroughs™

Breakthroughs™ is a public-interest PSA series created to help audiences better understand important advancements in science, medicine, technology, sustainability, infrastructure, and human progress. Each segment translates complex innovation into clear, credible, visually compelling public education — highlighting the larger human and societal impact behind emerging ideas, technologies, and organizations helping shape the future.
For more info:
https://www.psabreakthroughs.org

Lisa Meyers
OMD prm
+1 305-974-1346
email us here

This press release can be viewed online at: https://www.einpresswire.com/article/938904110

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.
© 1995-2026 Newsmatics Inc. All Right Reserved.